Matthew Herper· @matthewherper · X·· 25 天前AI 评分12
AI 导读
一位晚期非小细胞肺癌患者依靠突破性靶向药将病情控制长达15年,她在STAT峰会上讲述了这段经历。该患者同时致力于为其他患者倡导权益,也目睹了这些药物最终对其他患者倡导者失效的局限。相关报道聚焦其ROS1突变与克唑替尼治疗经历。
正文
Want a good, happy cry that will leave you with a better appreciation of targeted cancer drugs?
Watch this talk from the recent STAT Summit. Hear from a patient who has had late-stage non-small cell lung cancer for 15 years because a breakthrough drug has kept it in control. Hear how she has worked to advocate for others -- and also seen the limits of these amazing medicines as they eventually stopped helping other advocates she knew.
Really give this a watch/read. Worth your time, I swear.
https://www.statnews.com/2026/10/23/lung-cancer-patient-ros1-mutation-on-crizotinib/ via @statnews
来源:Matthew Herper · x.com